admaris的个人主页 - 老虎社区

admaris

admaris

暂无个人介绍

IP属地：未知

3关注

4粉丝

0主题

0勋章

2021-11-29

nice

Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant

2021-11-16

nice

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4098950502646600","uuid":"4098950502646600","gmtCreate":1635847908614,"gmtModify":1636582943513,"name":"admaris","pinyin":"admaris","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/f1ce3d6f8a55a5fe565e8e4779bf5174","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":3,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":600761941,"gmtCreate":1638198483826,"gmtModify":1638198483969,"author":{"id":"4098950502646600","authorId":"4098950502646600","name":"admaris","avatar":"https://static.tigerbbs.com/f1ce3d6f8a55a5fe565e8e4779bf5174","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098950502646600","authorIdStr":"4098950502646600"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600761941","repostId":"1188274579","repostType":4,"repost":{"id":"1188274579","kind":"news","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p>\n<p>Pfizer&nbsp;shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p>\n<p>Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p>\n<p>The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p>\n<p>Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding&nbsp; the drugmaker has the capability to make as many as 4 billion doses next year.</p>\n<p>Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p>\n<p>Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p>\n<p>Earlier this month,&nbsp;Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food &amp; Drug Administration, to the United States Department of Health and Human Services.</p>\n<p>At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck &amp; Co. MRK last month to buy&nbsp;1.7 million doses its 'molnupiravir' treatment&nbsp;of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding  the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1949,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871264573,"gmtCreate":1637074928904,"gmtModify":1637074929057,"author":{"id":"4098950502646600","authorId":"4098950502646600","name":"admaris","avatar":"https://static.tigerbbs.com/f1ce3d6f8a55a5fe565e8e4779bf5174","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098950502646600","authorIdStr":"4098950502646600"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871264573","repostId":"1108846823","repostType":4,"isVote":1,"tweetType":1,"viewCount":3004,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":871264573,"gmtCreate":1637074928904,"gmtModify":1637074929057,"author":{"id":"4098950502646600","authorId":"4098950502646600","name":"admaris","avatar":"https://static.tigerbbs.com/f1ce3d6f8a55a5fe565e8e4779bf5174","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098950502646600","idStr":"4098950502646600"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871264573","repostId":"1108846823","repostType":4,"repost":{"id":"1108846823","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637073553,"share":"https://www.laohu8.com/m/news/1108846823?lang=&edition=full","pubTime":"2021-11-16 22:39","market":"us","language":"en","title":"Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars","url":"https://stock-news.laohu8.com/highlight/detail?id=1108846823","media":"Tiger Newspress","summary":"Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars.Rivian (RIVN.US) ","content":"<p></p>\n<p>Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars.<img src=\"https://static.tigerbbs.com/5c173108ca81cbd959678e41253ff9a6\" tg-width=\"771\" tg-height=\"568\" referrerpolicy=\"no-referrer\">Rivian (RIVN.US) is in the final stage of negotiations on opening an automobile manufacturing and battery factory in the east of Atlanta, Georgia, USA. The source stressed that the negotiations have not yet been finalized and the details may change.</p>\n<p>It is reported that last week, it was reported that Rivian was actively looking for the location of an independent battery factory in addition to two new automobile assembly plants.</p>\n<p>At present, Rivian has built a factory in Normal, Illinois, USA, which produces the company's all-electric R1T pickup truck.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-16 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p></p>\n<p>Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars.<img src=\"https://static.tigerbbs.com/5c173108ca81cbd959678e41253ff9a6\" tg-width=\"771\" tg-height=\"568\" referrerpolicy=\"no-referrer\">Rivian (RIVN.US) is in the final stage of negotiations on opening an automobile manufacturing and battery factory in the east of Atlanta, Georgia, USA. The source stressed that the negotiations have not yet been finalized and the details may change.</p>\n<p>It is reported that last week, it was reported that Rivian was actively looking for the location of an independent battery factory in addition to two new automobile assembly plants.</p>\n<p>At present, Rivian has built a factory in Normal, Illinois, USA, which produces the company's all-electric R1T pickup truck.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108846823","content_text":"Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars.Rivian (RIVN.US) is in the final stage of negotiations on opening an automobile manufacturing and battery factory in the east of Atlanta, Georgia, USA. The source stressed that the negotiations have not yet been finalized and the details may change.\nIt is reported that last week, it was reported that Rivian was actively looking for the location of an independent battery factory in addition to two new automobile assembly plants.\nAt present, Rivian has built a factory in Normal, Illinois, USA, which produces the company's all-electric R1T pickup truck.","news_type":1,"symbols_score_info":{"RIVN":0.9}},"isVote":1,"tweetType":1,"viewCount":3004,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600761941,"gmtCreate":1638198483826,"gmtModify":1638198483969,"author":{"id":"4098950502646600","authorId":"4098950502646600","name":"admaris","avatar":"https://static.tigerbbs.com/f1ce3d6f8a55a5fe565e8e4779bf5174","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098950502646600","idStr":"4098950502646600"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600761941","repostId":"1188274579","repostType":4,"repost":{"id":"1188274579","kind":"news","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p>\n<p>Pfizer&nbsp;shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p>\n<p>Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p>\n<p>The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p>\n<p>Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding&nbsp; the drugmaker has the capability to make as many as 4 billion doses next year.</p>\n<p>Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p>\n<p>Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p>\n<p>Earlier this month,&nbsp;Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food &amp; Drug Administration, to the United States Department of Health and Human Services.</p>\n<p>At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck &amp; Co. MRK last month to buy&nbsp;1.7 million doses its 'molnupiravir' treatment&nbsp;of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding  the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1949,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}